La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Viatris a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Viatris..

Viatris (NASDAQ:VTRS) Azioni, Catena delle Opzioni

Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Inc

VIATRIS ORD

WIIM

RXST

RxSight shares are trading lower. The company reported Q3 financial results.

Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) with a Outperform and raises the price target from $30 to $32.

News

Price Target

Analyst Ratings

AORT

Oppenheimer Maintains Outperform on Artivion, Raises Price Target to $32

ASPCU

Trading Halt: Halt status updated at 11:00:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Oppenheimer analyst Colin Rusch maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Outperform and lowers the price target from $17 to $14.

ARRY

Oppenheimer Maintains Outperform on Array Technologies, Lowers Price Target to $14

Wedbush analyst Jay McCanless maintains Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) with a Neutral and raises the price target from $8 to $10.

RDFN

Wedbush Maintains Neutral on Redfin, Raises Price Target to $10

Oppenheimer analyst Tyler Batory reiterates Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) with a Outperform and raises the price target from $17 to $18.

Reiteration

APLE

Oppenheimer Reiterates Outperform on Apple Hospitality REIT, Raises Price Target to $18

The German State Criminal Police (LKA) has dismissed reports claiming OneCoin founder Ruja Ignatova was murdered, suggesting the notorious &#8220;Crypto Queen&#8221; &#8211; responsible for a $4 billion cryptocurrency fraud &#8211; may be alive and <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39509963/u-s-offers-5m-reward-for-information-on-crypto-fraudster-ruja-ignatova">hiding in South Africa.</a>
What Happened: Ignatova, who made the FBI&#8217;s Ten Most Wanted Fugitives List in 2022, has been on the run since October 2017 when she fled from Sofia to Athens following her U.S. indictment on charges of wire fraud, money laundering, and securities fraud.
The U.S. State Department maintains a $5 million reward for information leading to her arrest.
LKA Düsseldorf, leading the German investigation, has debunked documents suggesting Ignatova was murdered in 2018 and disposed of in the Ionian Sea. 
&#8220;We assume or are working with the hypothesis that Ruja Ignatova is still alive,&#8221; stated LKA spokeswoman Sabine Dässel, as <a href="https://www.spiegel.de/netzwelt/web/onecoin-deutsche-ermittler-halten-todesmeldung-zu-kryptoqueen-ruja-ignatova-fuer-falsch-a-fc6cd492-c961-4aed-b3dc-f69324597b88">reported</a> by Der Spiegel.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a>
The Bulgarian-born German national allegedly orchestrated one of history&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39139647/was-crypto-queen-ruja-ignatova-murdered-by-a-bulgarian-crime-head">largest fraud schemes</a> through OneCoin Ltd., which she launched in 2014, marketing it as a &#8220;Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) killer.&#8221; 
By 2017, investors worldwide had lost over $4 billion through the fraudulent cryptocurrency investment scheme.
Investigators are now focusing on South Africa, particularly Cape Town&#8217;s wealthy districts, where security sources report possible sightings. 
The area&#8217;s connection to OneCoin deepened after a 2023 incident involving the murder of a Bulgarian criminal who allegedly planned to testify to U.S. investigators.
While some assets have been recovered, including $10 million from London property sales, most investor funds remain unaccounted for. 
What&#8217;s Next: The ongoing investigation into OneCoin&#8217;s collapse and its implications for cryptocurrency regulation will be a key topic at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry experts will discuss fraud prevention and investor protection in digital assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Crypto Queen' Ruja Ignatova, OneCoin's $4 Billion Fraud Mastermind, Is Alive And In South Africa, German Police Suspects

Wedbush analyst Moshe Katri maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Outperform and raises the price target from $35 to $45.

TOST

Wedbush Maintains Outperform on Toast, Raises Price Target to $45

Oppenheimer analyst Colin Rusch maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Outperform and lowers the price target from $171 to $170.

Oppenheimer Maintains Outperform on Albemarle, Lowers Price Target to $170

ADMA

ADMA Biologics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and FY25 revenue guidance.

IOVA

Iovance Biotherapeutics shares are trading lower. The company reported Q3 financial results.

Wedbush analyst Michael Pachter maintains Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) with a Outperform and raises the price target from $19 to $20.

HEAR

Wedbush Maintains Outperform on Turtle Beach, Raises Price Target to $20

Wedbush analyst Scott Devitt maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Neutral and raises the price target from $37 to $38.

PINS

Wedbush Maintains Neutral on Pinterest, Raises Price Target to $38

Wedbush analyst Scott Devitt maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Outperform and raises the price target from $135 to $155.

ABNB

Wedbush Maintains Outperform on Airbnb, Raises Price Target to $155

Wedbush analyst Daniel Ives maintains Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) with a Outperform and raises the price target from $24 to $32.

CCSI

Wedbush Maintains Outperform on Consensus Cloud Solns, Raises Price Target to $32

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) analysts are cautious on the short-term outlook for the electric vehicle company with supply chain concerns, after the company missed third-quarter revenue and <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">earnings per share estimates.</a>
The Rivian Analysts: 
<ul>
<li>Truist analyst Jordan Levy maintained a Hold rating on Rivian with a $12 price target.</li>
<li>Wedbush analyst Daniel Ives maintained an Outperform rating with a $20 price target.</li>
<li>Needham analyst Chris Pierce reiterated a Buy rating and lowered the price target from $18 to $14.</li>
<li>Piper Sandler analyst Alexander Potter maintained an Overweight rating and lowered the price target from $21 to $19.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/equities/24/11/41832998/rivian-draftkings-block-pinterest-and-tesla-why-these-5-stocks-are-on-investors-radars-today">Rivian, Draftkings, Block, Pinterest, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Truist on RIVN: Proof of profitability for Rivian's R1 vehicle may be necessary to instill confidence in the R2 launch, Levy said in a new investor note.
"RIVN's third quarter results were mired by the company's previously reported component shortage, though a significant expected 4Q uptick in regulatory credit sales + realization of cost-down from Gen 2 models enabled the company to reiterate its 4Q positive GM (gross margin) target," Levy said.
The analyst said Rivian needs to demonstrate consistent profitability to help investors gain confidence.
Rivian's tailwind of resolving supply chain issues was not a surprise to investors, Levy added.
"While we are incrementally positive on the timeline reiteration for R2, we see the recent election results and the incoming administration being an overhang over the entire domestic EV market for the time being given the uncertainty."
Wedbush on RIVN: The electric vehicle company made progress and saw strong demand in the third quarter, but Ives said in a new investor note that there is more work ahead.
Ives said Rivian took two steps forward but one step back as the supply chain challenges hurt the company's plan to ramp up production.
"Rivian did not anticipate such large supply ramp challenges this quarter, however, it should be well sorted over the next few quarters as the company is still on track in terms of timing the R2 production launch," Ives said.
A supply partnership announced with LG on Thursday and the pending launch of the Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) joint venture are "critical pieces" for the future of Rivian, Ives added.
"Although we still remain confident in the long-term Rivian vision, it will take some serious strides for the company to regain trust in the short-term vision in the eyes of the Street."
Needham on RIVN: Scale and margins are bearish talking points for the Rivian story, Pierce said in a new investor note.
"We continue to view RIVN as a long-term winner in the eventual ICE to EV transition, leaning on its ability to create a brand and produce vehicles that drive high levels of customer passion and satisfaction," Pierce said.
The analyst said R2 production enhancements are the key focus for 2025 with R2 production set to begin in the first half of 2026. Vehicle profitability for the R2 is expected to be reached faster than the R1 and will be a key factor to watch, the analyst added.
The analyst also highlighted a joint venture with Volkswagen expected to close in the fourth quarter.
"RIVN's balance sheet has been significantly strengthened the Volkswagen announcement, removing any additional equity needs vs our prior model, allowing for a higher level of investor patience."
Piper Sandler on RIVN: The third-quarter results and commentary had no surprises, leading to increasing importance for the joint venture with Volkswagen closing as the next catalyst, Potter said in a new investor note.
"The stock has faltered recently, partially due to slower production, and partially (in our view) because a JV with Volkswagen has yet to be finalized," Potter said.
The analyst said the joint venture terms could continue to be a story in the coming weeks and could see Rivian's valuation expand.
"We will review our model once the JV terms are announced."
RIVN Price Action: Rivian stock is down 0.48% to $10.00 on Friday, versus a 52-week trading range of $8.26 to $24.62. Rivian stock is down 51% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41784487/rivian-lucid-stocks-sink-after-trump-win-whats-driving-bearish-move">Rivian, Lucid Stocks Sink After Trump Win: What&#8217;s Driving Bearish Move?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Trading Ideas

RIVN

VWAGY

Rivian Stock 'Long-Term Winner' In Gas-To-Electric Transition: Analyst

DraftKings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) stock initially traded lower on Friday but reversed course and began moving higher after the company reported third-quarter earnings and lowered its guidance for the 2024 fiscal-year after the bell <a href="https://www.benzinga.com//node/41826834">on Thursday</a>.
The Details: In the report, DraftKings reported a loss of 17 cents per share, beating analyst estimates of a loss of 42 cents per share. Furthermore, the company reported sales of $1.09 billion, missing analyst estimates of $1.11 billion. The reported sales figure represents a 38.6% year-over-year increase.
The company announced an increase in Monthly Unique Payers (MUPs) to 3.6 million, a growth of 55% year-over-year. It also reported Average Revenue per MUPs (ARPMUP) of $103, a 10% decrease compared to the same period last year.
&#8220;We achieved healthy results across our core value drivers in the&nbsp;third quarter&nbsp;with efficient customer acquisition and promotional reinvestment as well as improvement in our structural sportsbook hold percentage,&#8221; said Alan Ellingson, DraftKings&#8217; CFO. 
DraftKings revised its outlook for the 2024 fiscal-year. Specifically, it lowered its revenue guidance from between $5.05 billion and $5.25 billion to between $4.85 billion and $4.95 billion versus analyst estimates of $5.13 billion.
The company also introduced guidance for the 2025 fiscal-year. It anticipates revenue between $6.2 billion and $6.5 billion and adjusted EBITDA between $900 million and $1.0 billion.
Related Link: <a href="https://www.benzinga.com/news/24/11/41808861/whats-going-on-with-palantir-stock-thursday">What&#8217;s Going On With Palantir Stock Thursday?</a>
DKNG Price Action: At the time of publication, DraftKings shares are moving 5.05% higher at $40.95 , according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

DKNG

What's Going On With DraftKings Stock Friday?

BMO Capital analyst Tamy Chen maintains Lion Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEV#NYSE">LEV</a>) with a Market Perform and lowers the price target from $0.8 to $0.6.

BMO Capital Maintains Market Perform on Lion Electric, Lowers Price Target to $0.6

BMO Capital analyst James Thalacker maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Outperform and lowers the price target from $298 to $291.

BMO Capital Maintains Outperform on Constellation Energy, Lowers Price Target to $291

Avantor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) short percent of float has fallen 7.92% since its last report. The company recently reported that it has 33.09 million shares sold short, which is 4.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Avantor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731080721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Avantor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Avantor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Avantor's peer group average for short interest as a percentage of float is 5.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

AVTR

(AVTR) - Analyzing Avantor's Short Interest

Aquestive: Rare Opportunity With Dual Platform Strategy

In a report released today, Balaji Prasad from Barclays maintained a Sell rating on Viatris (VTRS – Research Report), with a price target of $11.00...

Viatris (VTRS) Receives a Sell from Barclays

Viatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growth

Viatris Non-GAAP EPS of $0.75, revenue of $3.8B

Viatris in charts: Revenue declines across product categories and markets in Q3

Notable gainers among liquid option names this morning include EPAM Systems (EPAM) $233.69 +31.00, Warner Bros. Discovery (WBD) $9.52 +1.14, Viatri...

Early notable gainers among liquid option names on November 7th

Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript

Viatris nears 11-month high after Q3 beat

Viatris Inc. 2024 Q3 - Results - Earnings Call Presentation

Analyst Jason Gerberry from Bank of America Securities reiterated a Sell rating on Viatris (VTRS – Research Report) and keeping the price target at...

Viatris Underperform Rating: Limited Growth Prospects and Conservative Capital Allocation Strategy

AQST

EPAM

GILD

SPRY

VTRS

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

General

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Dividends

Viatris Announces Third Quarter 2024 Dividend

Earnings

Viatris Reports Third Quarter Financial Results for 2024

LXRX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Viatris

Viatris (VTRS) Opzioni

Viatris (NASDAQ:VTRS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO